Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

David M. Ficker; M. Privitera; G. Krauss; A. Kanner; J. L. Moore; T. Glauser

doi:10.1212/01.wnl.0000172932.95985.51

Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

David M. Ficker, M. Privitera, G. Krauss, A. Kanner, J. L. Moore, T. Glauser

School of Medicine

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

Original language	English (US)
Pages (from-to)	593-595
Number of pages	3
Journal	Neurology
Volume	65
Issue number	4
DOIs	https://doi.org/10.1212/01.wnl.0000172932.95985.51
State	Published - Aug 23 2005

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/01.wnl.0000172932.95985.51

Cite this

@article{a27acb5c332b4fb6942f5dc4772b2c6f,

title = "Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine",

abstract = "The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.",

author = "Ficker, {David M.} and M. Privitera and G. Krauss and A. Kanner and Moore, {J. L.} and T. Glauser",

note = "Funding Information: Supported by Shire. Carbatrol is a registered trademark of Shire. ",

year = "2005",

month = aug,

day = "23",

doi = "10.1212/01.wnl.0000172932.95985.51",

language = "English (US)",

volume = "65",

pages = "593--595",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

AU - Ficker, David M.

AU - Privitera, M.

AU - Krauss, G.

AU - Kanner, A.

AU - Moore, J. L.

AU - Glauser, T.

N1 - Funding Information: Supported by Shire. Carbatrol is a registered trademark of Shire.

PY - 2005/8/23

Y1 - 2005/8/23

N2 - The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

AB - The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

UR - http://www.scopus.com/inward/record.url?scp=23844508153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844508153&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000172932.95985.51

DO - 10.1212/01.wnl.0000172932.95985.51

M3 - Article

C2 - 16116122

AN - SCOPUS:23844508153

SN - 0028-3878

VL - 65

SP - 593

EP - 595

JO - Neurology

JF - Neurology

IS - 4

ER -

Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this